日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy

一线塞米普利单抗治疗晚期非小细胞肺癌患者中,患者报告结局与总生存期之间的关联

Gandara, David R; Makharadze, Tamta; Gümüş, Mahmut; Gogishvili, Miranda; Sezer, Ahmet; Kim, Eric; Yan, Eric; Seebach, Frank; Harnett, James; Quek, Ruben G W

Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy

对 EMPOWER-Lung 1 研究中接受 cemiplimab 治疗与化疗治疗的晚期非小细胞肺癌患者的患者报告结局进行回顾

Gandara, David R; Gümüş, Mahmut; Kilickap, Saadettin; Sezer, Ahmet; Bondarenko, Igor; Özgüroğlu, Mustafa; Gogishvili, Miranda; Yan, Eric; Jia, Xue; Kim, Eric; Seebach, Frank; Quek, Ruben G W

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

作者更正:CTLA4阻断可消除KEAP1/STK11相关的PD-(L)1抑制剂耐药性

Skoulidis, Ferdinandos; Araujo, Haniel A; Do, Minh Truong; Qian, Yu; Sun, Xin; Cobo, Ana Galan; Le, John T; Montesion, Meagan; Palmer, Rachael; Jahchan, Nadine; Juan, Joseph M; Min, Chengyin; Yu, Yi; Pan, Xuewen; Arbour, Kathryn C; Vokes, Natalie; Schmidt, Stephanie T; Molkentine, David; Owen, Dwight H; Memmott, Regan; Patil, Pradnya D; Marmarelis, Melina E; Awad, Mark M; Murray, Joseph C; Hellyer, Jessica A; Gainor, Justin F; Dimou, Anastasios; Bestvina, Christine M; Shu, Catherine A; Riess, Jonathan W; Blakely, Collin M; Pecot, Chad V; Mezquita, Laura; Tabbó, Fabrizio; Scheffler, Matthias; Digumarthy, Subba; Mooradian, Meghan J; Sacher, Adrian G; Lau, Sally C M; Saltos, Andreas N; Rotow, Julia; Johnson, Rocio Perez; Liu, Corinne; Stewart, Tyler; Goldberg, Sarah B; Killam, Jonathan; Walther, Zenta; Schalper, Kurt; Davies, Kurtis D; Woodcock, Mark G; Anagnostou, Valsamo; Marrone, Kristen A; Forde, Patrick M; Ricciuti, Biagio; Venkatraman, Deepti; Van Allen, Eliezer M; Cummings, Amy L; Goldman, Jonathan W; Shaish, Hiram; Kier, Melanie; Katz, Sharyn; Aggarwal, Charu; Ni, Ying; Azok, Joseph T; Segal, Jeremy; Ritterhouse, Lauren; Neal, Joel W; Lacroix, Ludovic; Elamin, Yasir Y; Negrao, Marcelo V; Le, Xiuning; Lam, Vincent K; Lewis, Whitney E; Kemp, Haley N; Carter, Brett; Roth, Jack A; Swisher, Stephen; Lee, Richard; Zhou, Teng; Poteete, Alissa; Kong, Yifan; Takehara, Tomohiro; Paula, Alvaro Guimaraes; Parra Cuentas, Edwin R; Behrens, Carmen; Wistuba, Ignacio I; Zhang, Jianjun; Blumenschein, George R; Gay, Carl; Byers, Lauren A; Gibbons, Don L; Tsao, Anne; Lee, J Jack; Bivona, Trever G; Camidge, D Ross; Gray, Jhannelle E; Leighl, Natasha B; Levy, Benjamin; Brahmer, Julie R; Garassino, Marina C; Gandara, David R; Garon, Edward B; Rizvi, Naiyer A; Scagliotti, Giorgio Vittorio; Wolf, Jürgen; Planchard, David; Besse, Benjamin; Herbst, Roy S; Wakelee, Heather A; Pennell, Nathan A; Shaw, Alice T; Jänne, Pasi A; Carbone, David P; Hellmann, Matthew D; Rudin, Charles M; Albacker, Lee; Mann, Helen; Zhu, Zhou; Lai, Zhongwu; Stewart, Ross; Peters, Solange; Johnson, Melissa L; Wong, Kwok K; Huang, Alan; Winslow, Monte M; Rosen, Michael J; Winters, Ian P; Papadimitrakopoulou, Vassiliki A; Cascone, Tina; Jewsbury, Philip; Heymach, John V

Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications

解码非小细胞肺癌对免疫检查点抑制剂的耐药机制:血浆蛋白质组学及其治疗意义的综合分析

Harel, Michal; Dahan, Nili; Lahav, Coren; Jacob, Eyal; Elon, Yehonatan; Puzanov, Igor; Kelly, Ronan J; Shaked, Yuval; Leibowitz, Raya; Carbone, David P; Gandara, David R; Dicker, Adam P

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

在超过 8000 名涵盖 24 种癌症类型的患者中,肿瘤突变负荷与免疫检查点抑制剂治疗后的生存率之间的关系

Gandara, David R; Agarwal, Neeraj; Gupta, Shilpa; Klempner, Samuel J; Andrews, Miles C; Mahipal, Amit; Subbiah, Vivek; Eskander, Ramez N; Carbone, David P; Riess, Jonathan W; Sammons, Sarah; Snider, Jeremy; Bouzit, Lilia; Cho-Phan, Cheryl; Price, Megan; Li, Gerald; Quintanilha, Julia C F; Huang, Richard Sheng Poe; Ross, Jeffrey S; Fabrizio, David; Oxnard, Geoffrey R; Graf, Ryon P

Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types"

作者对“致编辑的信”的回应:“超过8000名24种癌症患者接受免疫检查点抑制剂治疗后的肿瘤突变负荷和生存率”

Graf, Ryon P; Gandara, David R

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study

一项Lung-MAP研究表明,ctDNA肿瘤比例升高与晚期非小细胞肺癌患者突变检出率提高相关,但总体生存率却更低。

Mack, Philip C; Redman, Mary W; Tukachinsky, Hanna; Kozono, David E; Minichiello, Katherine; Dragnev, Konstantin H; Tolba, Khaled A; Neal, Joel W; Madison, Russell W; Waqar, Saiama N; Aggarwal, Charu; Hirsch, Fred R; Patel, Jyoti D; Herbst, Roy S; Chiang, Anne C; Reckamp, Karen L; Kelly, Karen; Borghaei, Hossein; Gray, Jhanelle E; Gandara, David R

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.

帕博利珠单抗和曲美替尼治疗富含 KRAS 突变的晚期非小细胞肺癌的 1/1B 期试验

Riess Jonathan W, Lara Matthew S, Luxardi Guillaume, Lopez de Rodas Miguel, Shimoda Michiko, Kelly Karen, Lara Primo N, Beckett Laurel, Monjazeb Arta, Schalper Kurt A, Maverakis Emanual, Gandara David R

Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population

拉丁美洲肺癌患者的遗传祖先:了解多样化人群的关键一步

Castañeda-González, Juan Pablo; Parra-Medina, Rafael; Riess, Jonathan W; Gandara, David R; Carvajal-Carmona, Luis G

Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer

简报:脉冲剂量奥希替尼治疗EGFR突变型非小细胞肺癌软脑膜转移或难治性脑转移的安全性

Sun, Fangdi; Nagpal, Seema; Singhal, Surbhi; Neal, Joel W; Wakelee, Heather A; Myall, Nathaniel J; Bolan, Patrick; Riess, Jonathan W; Gandara, David R; Das, Millie S